Treatments during the observational period. Values in parentheses are percentages.
| UK, n = 147 | Japan, n = 312 | EUVAS, n = 254 | JMAAV, n = 48 | |
|---|---|---|---|---|
| Oral glucocorticoids | 145 (99.6) | 302 (96.8) | 254 (100) | 48 (100) |
| Maximum dose | 40 mg/day | 30 mg/day | Not done | 35 mg/day |
| Immunosuppressants | 140 (95.2) | 130 (41.7) | 254 (100) | 31 (64.6) |
| Cyclophosphamide | 112 (76.2) | 100 (32.1) | 252 (99.2) | 28 (58.3) |
| Cumulative dose | 6.3 g | 1.5 g | Not done | 2.7 g |
| Azathioprine | 98 (66.7) | 47 (15.1) | 230 (90.6) | 6 (12.5) |
| Mycophenolate | 51 (34.7) | 1 (0.3) | 18 (7.1) | 0 |
| Methotrexate | 11 (7.5) | 4 (1.3) | 3 (1.2) | 1 (2.1) |
| Cyclosporine | 2 (1.4) | 3 (1.0) | 4 (1.6) | 0 |
| Tacrolimus | 2 (1.4) | 4 (1.3) | 5 (2.0) | 1 (2.1) |
| Mizoribine | 0 | 13 (4.2) | 0 | 1 (2.1) |
| mPSL pulse | 39 (26.5) | 106 (34.0) | 44 (17.3) | 19 (39.6) |
| Plasma exchange | 24 (16.3) | 22 (7.1) | 51 (20.1) | 2 (4.2) |
| IV-IG | 13 (8.8) | 30 (9.6) | 1 (0.4) | 0 |
| Biologics | 40 (27.2) | 1 (0.3) | 1 (0.4) | 1 (2.1) |
| Rituximab | 32 (21.8) | 0 | 0 | 1 (2.1) |
| Infliximab | 2 (1.4) | 1 (0.3) | 1 (0.4) | 0 |
| Adalimumab | 7 (4.8) | 0 | 0 | 0 |
“Maximum dose” means the median maximum oral glucocorticoid dose converted to equivalent prednisolone dose during the observational period. “Cumulative dose” means the median cumulative cyclophosphamide dose during the observational period. EUVAS: European Vasculitis Society; JMAAV: Japanese patients from the MPO-ANCA-associated vasculitis trial; mPSL: methylprednisolone; IV-IG: intravenous immunoglobulins; MPO: myeloperoxidase; ANCA: antineutrophil cytoplasmic antibody.